A5056135111- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Economic and Financial Impacts of Cancer
- Lymphoma Diagnosis and Treatment
- Renal cell carcinoma treatment
- Multiple and Secondary Primary Cancers
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Cancer, Hypoxia, and Metabolism
- Gastric Cancer Management and Outcomes
- Autoimmune and Inflammatory Disorders Research
- Bladder and Urothelial Cancer Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Viral-associated cancers and disorders
- Multiple Myeloma Research and Treatments
- Neutropenia and Cancer Infections
- Neuroblastoma Research and Treatments
- Cancer Research and Treatments
- CAR-T cell therapy research
Mount Sinai Medical Center
2015-2025
Sylvester Comprehensive Cancer Center
2023-2024
Mayo Clinic in Florida
2019
Aventura Hospital and Medical Center
2018
University of California, Los Angeles
2014
Fairchild Tropical Botanic Garden
2014
Palmetto Hematology Oncology
2011
University of Maryland, Baltimore
2003-2004
U-M Rogel Cancer Center
2004
University of Baltimore
2003
To analytically and clinically validate microsatellite instability (MSI) detection using cell-free DNA (cfDNA) sequencing.
Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed objective response rate (ORR) of 36% in 66 patients who progressed ICI and targeted therapy. Herein, we report independent review committee (IRC)-assessed outcomes 153 treated lifileucel large multicenter Phase 2 therapy trial melanoma.Eligible had that...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. trial updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. We present final prespecified overall survival (OS) analysis of open-label, phase III CLEAR study treatment-naïve...
677 Background: Ethnic and racial disparities in oncology clinical trial participation continue to pose significant challenges. Despite initiatives by the NCI FDA address these through policies established 2017, notable gaps both cancer treatment involvement persist. There is a lack of comprehensive data regarding minority trials for FDA-approved urothelial therapies post-COVID-19 context. Methods: From 2020 2024, we examined from 2,755 patients recruited eight industry-sponsored (BCL2001,...
25 Background: It is known that ethnic and racial inequality in participation oncology clinical trial a contemporary problem. Efforts have been made by NCI FDA to address cancer disparities as per new policies placed 2017. Despite these efforts, there are still treatment participation. There paucity of data minorities the post COVID-19 era approved agents Prostate Cancer. Methods: From 2020-2024, total 4,744 patients participated seven trials (MAGNITUDE, TALAPRO-2, VISION, PROPEL, ARASENS,...
452 Background: Ethnic and racial disparities in oncology clinical trial participation remain a pressing challenge. Despite initiatives by the NCI FDA since 2017 aimed at addressing these disparities, significant gaps persist cancer treatment access involvement for minority populations. Notably, data on trials FDA-approved renal cell carcinoma treatments during post-COVID-19 era is limited. Methods: From 2020 to 2024, we analyzed from 2,940 patients enrolled five (CheckMate 9ER, CLEAR,...
Collective evidence points to a prominent role of stress in cancer growth and metastasis.Despite these results an etio-pathogenetic has not been widely accepted.Reasons controversies are the coexistence stressed patients high risk habits, sample size, heterogeneity retrospective origins studies.Experimental data clinical observations argue about possibility interaction between psychosocial events tumours.However number involved variables long period observation prevent with current...
e19523 Background: Patients undergoing chemotherapy often complain of alterations taste (dysgeusia), for which no conventional therapy exists. The African fruit Synsepalum dulcificum, or "Miracle Fruit" (MF), has been described as a powerful alteration product, converting sour to sweet taste. We conducted single institution trial assess whether the MF improves dysgeusia. Methods: with performance status 2 less, receiving cyclophosphamide, carboplatin, cisplatinum, gemcitibine, methotrexate,...
Pathogenic germline variants (PGVs) may be under-detected as causative etiologies in patients with non-small cell lung cancer (NSCLC). The prevalence of PGVs has been reported between 1 and 15% patients, depending on the patient population. rate within Hispanic/Latinx populations remains unknown. We retrospectively analyzed genomic results (Guardant360, Redwood City, CA, USA) 878 advanced or metastatic NSCLC at five centers South Florida, USA, from 2019 to 2022 analyze incidental (iPGVs)...
Characterized by the development of hundreds to thousands colonic adenomas, classic familial adenomatous polyposis (FAP) is one most common hereditary syndromes associated with an increased risk colorectal cancer. Several studies have attempted correlate specific APC mutations clinical phenotype.6 However, there considerable variability in expression phenotypes within families and among individuals identical mutations.7A 30 year-old Hispanic female presented emergency department a 2-week...
Introduction. Characterized as an undifferentiated, neuroendocrine tumor arising from totipotent stem cells, small-cell carcinoma (SCC) most commonly arises the lung. Extrapulmonary carcinomas (ESCC) are rare and account for only four percent of SCC. Gastric ESCC, more seen in Japanese male patients their seventh decade life, accounts approximately 0.1 ESCC. Case Presentation. A 75-year-old Hispanic presented with a several week history worsening epigastric pain nausea vomiting. Computer...
4117 Background: Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small molecule inhibitor of multiple signaling pathways including polo-like kinase 1 (PLK1) phosphoinositide 3-kinase (PI3K), has shown efficacy in preclinical pancreatic cancer models. In this study, rigosertib was assessed combination with gemcitabine patients treatment-naïve metastatic adenocarcinoma. Methods: Patients adenocarcinoma the pancreas were randomized 2:1 fashion to 1000 mg/m2 weekly for 3 weeks 4-week...
Typical bronchial carcinoid tumors are known for their relatively indolent behavior. There only four reported cases in the medical literature describing typical carcinoids metastasizing to brain. Little is about pathogenesis and presentation of this disease due very small patient population.A 67-year-old Hispanic female presented our hospital with a three-week history right arm numbness poor coordination. Computed tomography (CT) intravenous contrast brain subsequent magnetic resonance...
<h3>Background</h3> Despite improved outcomes in advanced (unresectable or metastatic) melanoma, many patients progress after ICI,<sup>1-3</sup> and have low response rates to subsequent therapy.<sup>4-7</sup> Lifileucel, a one-time autologous TIL cell therapy, demonstrated an investigator-assessed ORR of 36% Cohort 2 (C2), which enrolled 66 who progressed post-ICI appropriate targeted therapy.<sup>8,9</sup> We now report 153 across C2 C4 (NCT02360579), representing the largest phase study...
Cutaneous malignant melanoma is an aggressive cancer that contributes significantly to cancer-related mortality. Over the years, a deeper scrutiny of biology has led identification diverse evolutionary patterns involving various genetic pathways. This study attempts further understand landscape cutaneous in terms loco-regional variations and potential. Thirty-five cases were retrieved from archives classified based on location primary tumor presence or absence metastatic disease....